United Therapeutics (UTHR) Stock

Are you looking for ways to choose powerful stocks that can outperform the market for your investment portfolio? The Zacks Style Scores can help you with that.

Investors looking at stocks in the Medical - Drugs sector may be familiar with United Therapeutics (UTHR) and Stevanato Group (STVN). However, which of these two stocks is more appealing for value investors?

No matter if you invest in value, growth, or momentum stocks, the Zacks Style Scores can help you identify strong stocks more easily. This is one of the key features of the Zacks Premium research service.

No matter if you invest in value, growth, or momentum stocks, the Zacks Style Scores can help you identify strong stocks more easily. This is one of the key features of the Zacks Premium research service.

UTHR has strong advantages, such as high capital returns and effective profit reinvestment, which create a positive outlook. In the third quarter of fiscal year 2024, United Therapeutics reported impressive growth in its main products, with Tyvaso, Orenitram, and Unituxin all showing significant year-on-year increases. I estimate that the company's earnings could grow by 40% in the next 2-3 years.

United Therapeutics is a top company in treating pulmonary arterial hypertension (PAH), mainly due to its main product, Tyvaso, which generates most of its income. The company is also making advancements in organ transplants and bioengineered organs, such as xenotransplantation and ex vivo lung perfusion, which could change the industry. However, ongoing legal disputes, especially with Liquidia, pose risks to United Therapeutics' intellectual property and could impact its position in the PAH market.

Since I recommended buying United Therapeutics Corporation's stock in 2020, it has increased by more than 300%, mainly due to strong sales of Tyvaso DPI and other treatments for pulmonary arterial hypertension (PAH). Even with competition from generic drugs, the company has shown strength by using legal strategies and developing new products to safeguard and enhance its income. The company's future success will depend on increasing the market for Tyvaso DPI and progressing its pipeline, which includes exciting treatments for idiopathic pulmonary fibrosis (IPF) and innovative organ transplant technologies.

No matter if you invest in value, growth, or momentum, discovering solid stocks is simpler with the Zacks Style Scores, which is a key part of the Zacks Premium research service.

No matter if you invest in value, growth, or momentum stocks, the Zacks Style Scores can help you identify strong stocks more easily. This is one of the key features of the Zacks Premium research service.